Agenus - Stock Price History | AGEN
Historical daily share price chart and data for Agenus since 2023 adjusted for splits. The latest closing stock price for Agenus as of January 27, 2023 is 2.63.
- The all-time high Agenus stock closing price was 315.78 on March 09, 2000.
- The Agenus 52-week high stock price is 3.37, which is 28.1% above the current share price.
- The Agenus 52-week low stock price is 1.25, which is 52.5% below the current share price.
- The average Agenus stock price for the last 52 weeks is 2.43.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Agenus Historical Annual Stock Price Data |
| Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
| 2022 |
2.4495 |
3.4700 |
3.4700 |
1.3000 |
2.4000 |
-25.47% |
| 2021 |
4.3285 |
3.2300 |
6.6300 |
2.5600 |
3.2200 |
1.26% |
| 2020 |
3.5027 |
4.0400 |
5.2000 |
1.9200 |
3.1800 |
-21.87% |
| 2019 |
3.0215 |
2.5100 |
4.4000 |
2.1700 |
4.0700 |
71.01% |
| 2018 |
3.0122 |
3.5400 |
6.0400 |
1.5900 |
2.3800 |
-26.99% |
| 2017 |
3.9090 |
4.1600 |
5.3700 |
3.2400 |
3.2600 |
-20.87% |
| 2016 |
4.5745 |
4.4600 |
7.3600 |
2.7200 |
4.1200 |
-9.25% |
| 2015 |
6.1392 |
3.9800 |
9.7800 |
3.8800 |
4.5400 |
14.36% |
| 2014 |
3.2013 |
2.7800 |
5.1000 |
2.4100 |
3.9700 |
50.38% |
| 2013 |
3.6174 |
4.2400 |
4.9300 |
2.4000 |
2.6400 |
-35.61% |
| 2012 |
4.6131 |
2.1700 |
7.0400 |
2.1000 |
4.1000 |
105.00% |
| 2011 |
4.3574 |
6.3600 |
6.6600 |
2.0000 |
2.0000 |
-67.00% |
| 2010 |
5.3960 |
3.8556 |
8.2800 |
3.6006 |
6.0600 |
57.81% |
| 2009 |
7.1504 |
2.8800 |
17.9400 |
1.8000 |
3.8400 |
33.33% |
| 2008 |
10.4911 |
12.4800 |
18.1800 |
2.4600 |
2.8800 |
-76.47% |
| 2007 |
14.9767 |
11.5200 |
26.5800 |
9.4200 |
12.2400 |
11.48% |
| 2006 |
16.6496 |
28.7400 |
41.4600 |
9.2400 |
10.9800 |
-61.55% |
| 2005 |
37.7911 |
60.0000 |
60.0000 |
28.5600 |
28.5600 |
-52.96% |
| 2004 |
51.7704 |
68.7600 |
73.0800 |
28.3200 |
60.7200 |
-10.76% |
| 2003 |
66.5551 |
64.2000 |
94.8000 |
42.7800 |
68.0400 |
10.74% |
| 2002 |
65.3534 |
92.9400 |
100.9800 |
41.1660 |
61.4400 |
-37.56% |
| 2001 |
95.8940 |
66.3600 |
120.6000 |
64.5000 |
98.4000 |
48.28% |
| 2000 |
117.9851 |
277.5000 |
315.7800 |
63.7800 |
66.3600 |
0.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.744B |
$0.296B |
|
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
|
